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ABSTRACT
The transcription start sites (TSS) and promoters of
many genes are located in upstream CpG islands.
Methylation within such islands is known for both
imprinted and oncogenes, although poorly studied
for other genes, especially those with complex
CpG islands containing multiple first exons and
promoters. The glucocorticoid receptor (GR) CpG
island contains seven alternative first exons and
their promoters. Here we show for the five GR
promoters activated in PBMCs that methylation
patterns are highly variable between individuals.
The majority of positions were methylated at levels
>25% in at least one donor affecting each promoter
and TSS. We also examined the evolutionarily
conserved transcription factor binding sites (TFBS)
using an improved in silico phylogenetic footprinting
technique. The majority of these contain methylata-
ble CpG sites, suggesting that methylation may
orchestrates alternative first exon usage, silencing
and controlling tissue-specific expression. The
heterogeneity observed may reflect epigenetic
mechanisms of GR fine tuning, programmed by
early life environment and events. With 78% of evo-
lutionarily conserved alternative first exons falling
into such complex CpG islands, their internal struc-
ture and epigenetic modifications are bound to be
biologically important, and may be a common tran-
scriptional control mechanism used throughout
many phyla.
INTRODUCTION
Methylation of cytosine residues is a major epigenetic
mechanism in mammalian cells, and the only
known endogenous covalent DNA modiﬁcation (1).
Mammalian DNA methylation occurs on both DNA
strands at the 50 cytosine in a CpG pair. CpG dinucleo-
tides are the least frequent nucleotide pairs and they are
distributed in clusters, or CpG islands, throughout the
genome. Using the classical CpG island deﬁnition (2),
there are approximately 29000 CpG islands (each greater
than 200bp long, containing >50% GC and with an
observed/expected CpG ratio of >0.6) representing
 1% of the human genome. Overall 60–90% of genomic
CpGs are thought to be methylated (3–5), and this is
largely determined by their location within the genome.
CpG pairs outside of CpG islands are usually methylated,
those within such islands have long been thought to be
protected against methylation. More recent studies have
shown that CpG islands, in particular of tumor speciﬁc
genes (e.g. SPHK1) can also be methylated (6).
DNA methylation plays an important role in gene reg-
ulation and diﬀerential gene silencing. In all organisms
investigated, methylation patterns are maintained during
mitosis. During meiosis parental genomes are demethyl-
ated and individual foetal methylation patterns are estab-
lished during embryogenesis. Evidence from monozygotic
twins suggests that the foetal environment tightly regulates
methylation patterns: diﬀerences between monozygotic
twins only develop after birth, increasing with age when
global methylation levels fall (7). X-chromosome inactiva-
tion, and gene imprinting, both methylation dependent,
occur at this early stage of development (8). DNA methyl-
ation studies have, largely, been limited to less than
100 genes known to be imprinted (9). However, DNA
methylation is not limited to imprinted regions. More
recently it has been suggested that DNA methylation
outside these imprinted regions may underlie long-term
programming eﬀects, especially perinatally (10,11).
Methylation patterns established during embryogenesis
vary signiﬁcantly between tissues. Although a role for
DNA methylation in tissue-speciﬁc gene expression was
suggested already in 1975 (12,13), it was not until recently
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et al. (14) who identiﬁed some 150 such regions. In vivo,
embryonic stem cells diﬀerentiating for instance to neuro-
nal precursor cells and astrocytes undergo gradual tissue-
speciﬁc methylation, particularly in CpG islands. In vitro,
these cells become hypermethylated after extended prolif-
eration (15,16). Also, astroglial diﬀerentiation is asso-
ciated with demethylation of JAK-STAT pathway genes
(17,18).
CpG islands frequently contain transcription start sites
(TSS) and 50 promoter regions of housekeeping genes as
well as tissue-speciﬁc genes. Although it is now recognised
that methylation also occurs in CpG islands, the role
of methylation of promoter elements in CpG islands,
especially those associated with non-imprinted or non-
oncogenes, has received little attention. Detailed examina-
tion of mRNA transcripts has recently shown that the vast
majority of human genes show signiﬁcant diversity in their
50 region (19). Currently, it is estimated that more than
50% of genes possess alternative 50 TSS each with its own
promoter (20). On average genes have 3.1 promoters, but
they can have as many as 10 alternative promoters and
TSS (21). Evolutionarily conserved alternative promoters,
identiﬁed by inter-species sequence homology, were pre-
dominantly (78%) located within CpG islands upstream
of housekeeping or ubiquitously expressed genes. This
raises the question as to the relations between CpG
methylation and transcript variability within CpG islands
and their roles, especially in the context of ubiquitously
expressed, but tightly controlled genes. Although diﬀeren-
tial methylation of these sensitive regions may play a
critical role in the regulation of many genes, there are
very few studies where methylation patterns have been
analysed within a single complex CpG island containing
multiple ﬁrst exons and alternative promoters.
The type II glucocorticoid receptor (GR, OMIM
+138040; NR3C1) is an ubiquitously transcribed nuclear
hormone receptor with an unusually complex promoter
structure. GR transcription is controlled through nine pro-
moters each associated with an alternative TSS, seven of
which are found in an upstream CpG island (22,23). This
transcript variability does not alter the protein produced
since the ATG translation start codon is in exon 2. We and
others have hypothesised that TSS usage, resulting in dif-
ferential GR tissue expression proﬁles depends on short,
immediately upstream proximal promoter regions within
the CpG island. The GR and glucocorticoids (GC) are
involved in many physiological processes, and play a
major role in the hypothalamus-pituitary-adrenal (HPA)
response to stress. This is a highly regulated system, con-
trolled by GC feedback to the hippocampus and hypotha-
lamus. This system is also known to be susceptible to
diﬀerential methylation (24). Variability in HPA axis feed-
back sensitivity in the rat has been explained by changes in
methylation of the transcription inducing nerve growth
factor inducible-A (NGFI-A, also called KROX, EGR1,
or ZIF286) binding site in the promoter of exon 17.A s
most other GR promoters, 17 is located in an upstream
CpG island (25,26). We investigate here the positions and
levels of CpG methylation of GR alternative exons
and their promoters in order to understand the role and
pattern of methylation in the CpG island upstream of a
gene containing a complex promoter structure.
For this purpose, we have analysed diﬀerential methyl-
ation of alternative GR promoters in peripheral blood
mononuclear cells (PBMC) by bisulphate sequencing.
We have previously shown that PBMC express almost
all alternative ﬁrst exons (e.g. 1B, C, D, E, F and H)
(22). We also examine the evolutionarily conserved
TFBS pattern using an improved in silico phylogenetic
footprinting technique. The majority of CpG positions
in conserved TFBS were methylatable, and methylation
patterns were highly individualised among donors. The
heterogeneity of methylation patterns observed in our
study may reﬂect diﬀerences in early life environment
and events.
MATERIALS AND METHODS
Genomic alignments
Genomic DNA of the human chromosome 5 (July 2004,
UCSC) was aligned with rat (AJ271870, NCBI), mouse
(NCBIM35:18:39863309:39869358:1, Ensembl), chimpan-
zee (CHIMP1A:5:149403812:149409861:1, Ensembl) and
cow (ChrUn.313:334239:339538:1, Ensembl) sequences
upstream of the GR exon 2 using Vector NTi 10.1.1
(Invitrogen, Paisley, UK) as previously reported (27).
In silico phylogenetic footprinting (ISPF)
Genomic sequences predicted by homology to contain
the promoter regions of exons 1D, 1E, 1F and 1H were
screened for potential transcription factor binding sites
(TFBS) using the MATCH algorithm (28) from
TRANSFAC Professional (version 10.1). The cut-oﬀ
values for the core and matrix similarity scores of accept-
able binding site predictions were set to 0.98 and 0.95,
respectively (1.0=exact match). TRANSFAC-predicted
binding sites were transposed onto the multi-species geno-
mic alignment to identify coincident sites. The results
were expressed as the number of species where the ﬁrst
nucleotide of identical transcription factor matrices
coincide for each position within the alignment.
Subjects
Twenty-six healthy subjects (22 female and 4 male, age
range 35–67 years, mean 51 8 years) were recruited
by the Department of Psychobiology, University of
Trier, Germany. The study protocol was approved by
the ethics committee of the Rheinland-Pfalz State
Medical Association and written informed consent was
given by all participating subjects.
Exclusion criteria were based on medical history and
physical examination. They were designed to minimize
the inﬂuence of disease and drugs, and included: steroid
use (except for oral contraception or hormone replace-
ment therapy due to menopause); infections during the
preceding 2 weeks; dietary weight loss of 5kg or more
within 6 weeks before study entry; pregnancy or breast-
feeding; alcohol or drug dependence; severe allergies;
hematological, endocrine, cardiovascular, pulmonary,
7208 Nucleic Acids Research, 2008, Vol. 36, No. 22gastrointestinal, renal, hepatic, autoimmune or psychiatric
disorders. The subjects were also evaluated with the
German version of the Structured Clinical Interview for
DSM-IV (29) to exclude major depression disorder. From
each subject, one blood sample was collected between
08:30 and 09:00 hours under basal conditions.
Isolation of genomicDNA from PBMCs
Human PBMCs were puriﬁed from heparinised blood by
Ficoll-Isopaque (Amersham, UK) using Leucosep tubes
(Greiner Bio-one, Germany). After three washes in
HBSS (Biowhittaker, Verviers, Belgium), cells were resus-
pended in RPMI, 10% FBS, 10% DMSO and stored in
liquid nitrogen until further analysis. For DNA isolation,
cells were washed and resuspended in 2ml of PBS. DNA
was puriﬁed using the QIAamp DNA Blood Midi kit
(Qiagen, Venlo, The Netherlands) and stored at –208C.
Bisulphite treatment
The EpiTect Bisulﬁte kit (Qiagen) converts unmethylated
cytosine residues to uracil, whereas methylated cytosines
remain unmodiﬁed. According to the manufacturers’ pro-
tocol, the ﬁrst two steps of bisulphite treatment were per-
formed on 400ng of genomic DNA. The thermal cycler
(Mastercycler gradient, Eppendorf, Hamburg, Germany)
program comprised several incubation steps for DNA
denaturation, sulphonation of unmethylated cytosine,
and deamination of cytosine sulphonate to uracil sulpho-
nate. Cycling conditions were as follows: ﬁrst denatura-
tion for 5min at 998C, ﬁrst incubation for 25min at 608C,
second denaturation for 5min at 998C, second incubation
for 85min at 608C, third denaturation for 5min at 998C,
third incubation for 175min at 608C and hold at 208C.
Alkaline uracil desulphonation and sample puriﬁcation
were performed using a spin column. Modiﬁed DNA
was eluted and stored at –208C until analysis.
PCRs andmethylation quantification
The bisulphite-modiﬁed DNA was used to amplify
promoters of exons 1D, 1E, 1F and 1H with the primers
and under the conditions shown in Table 1.
PCR was performed using 20mM Tris–HCl (pH 8.4),
50mM KCl, 200mM deoxynucleoside triphosphates,
1  SyBR Green and 2.5U Platinum Taq DNA polymerase
(Invitrogen, Merelbeke, Belgium) on an Opticon 2 thermal
cycler (MJ Research). Cycling conditions were as follows:
958C for 2min, 40 cycles, at 958C for 20s, annealing tem-
perature (Table 1) for 20s and 728C for 25s. Products of
DB,E ,F A,F B,F C,H A,H B,H C and HD PCRs were used
as a template (20-fold dilution) for nested ampliﬁcations
using the primers and conditions in Table 1.
Methylation analysis of promoter 1D, 1E, 1H and the
215 ﬁrst nucleotides of promoter 1F were determined
manually. Such peak intensity-based quantiﬁcation has
previously been validated for methylation quantiﬁcation
(30). The nested PCR products (DBII,E II,F AII,F BII,F CII,
HAII,H BII,H CII,H DII and HDIII) and the DA PCR
products were directly sequenced after spin column puri-
ﬁcation (Genomed, Lo ¨ hne, Germany).
Methylation analysis of the promoter 1F proximal area
(FCII) was determined by multiple trace single population
quantiﬁcation. The FCII semi-nested PCR products were
cloned into the pCR4-TOPO vector (Invitrogen) and used
to transform Top10 electrocompetent E. coli (Invitrogen).
For each subject, 10–12 clones were sequenced using
100nM M13 primers and the BigDye 3.1 Terminator
cycle sequencing reagent (Applied Biosystems,
Nieuwerkerk, The Netherlands) on the ABI 3130 sequen-
cer (Applied Biosystems). Methylation percentage at each
position is calculated from the ratio of the numbers of
methylated to unmethylated colonies.
RESULTS
Identification of known TFBSby ISPF
ISPF was performed over all genomic regions containing
GR promoters with experimentally identiﬁed transcription
factors (Table 2). The genomic DNA of the complete CpG
islands of the ﬁve species, the mouse, rat, cow, chimpanzee
and man were aligned. The coincidental predictions of the
TRANSFAC analyses and genomic alignment identiﬁed
the evolutionarily conserved transcription factors.
Transcription factors have been experimentally identiﬁed
for promoters 1B (31), 17 [1F homologue, (25)] and prob-
ably 1D (32).
ISPF analysis identiﬁes two of the three known Yin
Yang-1 (YY1) sites in promoter 1D, at position -4819
and -4603. The third known YY1 site (-4642 from ATG)
was missed because of a discrepancy between the aligned
genomic sequences and both the complete and core
TRANSFAC matrices. The observed core was ATGGT
rather than the expected ATGGC. Reducing the strin-
gency of the TRANSFAC search correctly identiﬁes
this YY1 binding site, although with a much increased
risk of false positive predictions (data not shown).
Similarly, ISPF analysis of promoter 1F identiﬁes
the NGFI-A-binding site as being conserved between all
species, after its initial identiﬁcation in the homologous
rat promoter 17. ISPF analysis of the constituative pro-
moter 1B, successfully predicts the three known SP1
sites (31).
Epigenetic sequence coverage
We previously showed that exons 1B–1H are diﬀerentially
expressed in immune cells (22). Most of the ﬁve promoter
regions were successfully bisulphite-sequenced in PBMCs.
Multiple ampliﬁcations (nine nested and one simple
reaction, Figure 1) were required to cover 78% of the
relevant promoters (1274 nucleotides) representing 40%
of the total CpG island of 3.2kbp.
For some promoters it was not possible to get a com-
plete sequence because of diﬃculties in amplifying long
stretches of identical nucleotides after bisulphite modiﬁca-
tion. However, all conserved TFBS within the promoters
of interest except YY1 (-4814, 1D) were completely
sequenced.
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YY1-binding sites at -4814/9 and -4603/8 include dinu-
cleotides CpG
1, CpG
16 and CpG
17 (Figure 2). The CpG
dinucleotide in the core binding site (ggCGccatctt) is
known to be functionally sensitive to cytosine methylation
(33). Among 26 donors none were methylated in CpG
1,
while two and one donor, respectively had <25% methyl-
ation at CpG
16 or CpG
17. Similarly, ISPF analysis
predicts within promoter 1D, 90–94bp before the
transcription start site a core TTCCG matrix (from
either ELK-1 or c-Ets-1, both sharing the same core
matrix). The predicted complete binding site for these
two factors covers three CpG di-nucleotides (CpG
18-20,
Figure 2). CpG
19 forms part of the core matrix of
ELK-1 and c-Ets-1. Between 25% and 50% methylation
Table 1. PCR primers and reaction conditions for bisulphite sequencing
Primer sequence
a Ampliﬁed region
b Length
(bp)
Tm
(8C)
c
[MgCl2]
(mM)
[Primers]
(mM)
Promoter 1D
DA Fwd: 50-ATATTAGATAATGTATAGGGAATYGTTTAT-30
Rev: 50-CCRCCRCCATCTTAATAAAATACAATATC-30
-4724 to -4584 140 49 2 0.5
DB Fwd: 50-TGTTAAGATGGTGGTYGYGGGGAYGG-30
Rev: 50-AACTACCRCAACTCCACCTAATCC-30
-4644 to -4438 206 59 2 0.1
DBII Fwd: 50-GGTYGYGGGGAYGGGTTGGYGATATTGT-30
Rev: 50-CCTACTCRAACRCTCRACCACAACC-30
-4632 to -4460 172 59 1 0.1
Promoter 1E
E Fwd: 50-GGGAGTTGAAYGTTGGTATTTTAAAGTTG-30
Rev: 50-CTCRAAAAAAATTACACRCCAAATAC-30
-4129 to -3781 348 54 2 0.1
EII Fwd: 50-GTATTTTGTTTTATTTGTAGGGGTAGG-30
Rev: 50-TACAAAACCTCCAACRAACTAAATT-30
-4097 to -3804 293 55 1 0.1
Promoter 1F
FA Fwd: 50-TGAAGATTYGGTYGTTTAGATGAT-30
Rev: 50-ACCRAATTACRTAAAATATATCACTTCRAA-30
-3605 to -3378 227 50 2 1
FAII Fwd: 50-TGGTGGGGGATTTGTYGGTAYGYGA-30
Rev: 50-TCACTTCRAAAAAAACTACRAAATTACA-30
-3577 to -3398 179 52 2 0.5
FB Fwd: 50-GGTYGAGAYGTTGYGGTATYGTTTTYGTG-30
Rev: 50-CCTTAACRACAAACRCCRCCAATAC-30
-3452 to -3268 184 50 4 1
FBII Fwd: 50-GTTGYGGTATYGTTTTYGTGTAATTT-30
Rev: 50-ACRAATAACAACRAACRAACCACAA-30
-3443 to -3297 146 53 2 0.1
FC Fwd: 50-TTGTGGTTYGTTYGTTGTTATTYGTAGG-30
Rev: 50-CACCRAATTTCTCCAATTTCTTTTCTC-30
-3321 to -3177 144 54 2 1
FCII Fwd: 50-TTGTGGTTYGTTYGTTGTTATTYGTAGG-30
Rev: 50-CAATTTCTTTTCTCRCTACCTCCTTCC-30
-3321 to -3190 131 52 2 0.5
Promoter 1H
HA Fwd: 50-TTYGGTTGYGGYGGGAATTGYGGAYGGTG-30
Rev: 50-AAACTAATAAAAATTTATAAACTCC-30
-2422 to -2258 164 56 2 0.5
HAII Fwd: 50-GGTGGYGGGYGAGYGGTTTTTTTGTTAGAG-30
Rev: 50-ACTCCCRCRACRACCCCCRAATTATCTC-30
-2397 to -2276 121 58 1 0.1
HB Fwd: 50-GGGYGYGTTYGTTTTTTYGAGGTGTYGTTG-30
Rev: 50-CTCCCCCTCRACCCRACCAAA-30
-2341 to -2135 206 55 1 0.1
HBII Fwd: 50-GAGATAATTYGGGGGTYGTYGYGGGAG-30
Rev: 50-ACCCRACCAAAAAACRCCTAC-30
-2305 to -2145 160 56 1 0.1
HC Fwd: 50-TTTYGTAGGYGTTTTTTGGTYGGGTYGAG-30
Rev: 50-AATTCAAACRCRACTTAACRTTCACCACRAA-30
-2169 to -1967 202 51 2 1
HCII Fwd: 50-TTTYGTAGGYGTTTTTTGGTYGGGTYGAG-30
Rev: 50-CCAAAATTCCCRCRAAAAATAAAAAACTC-30
-2169 to -2055 114 55 3 0.1
HD Fwd: 50-GGTYGTTYGATATTYGTTTTYGTGGTG-30
Rev: 50-CCCRCTTATACACCCTCAC-30
-2015 to -1844 171 52 1 0.1
HDII Fwd: 50-GTGGTGAAYGTTAAGTYGYGTTTG-30
Rev: 50-CCRCACRCCCTCCTCAAACCA-30
-1994 to -1868 126 53 2 0.1
HDIII Fwd: 50-GGTYGTTYGATATTYGTTTTYGTGGTG-30
Rev: 50-CCRCACRCCCTCCTCAAACCA-30
-2015 to -1868 147 52 1 1
aFwd, forward or sense primer; Rev, reverse or antisense primer. Degenerate nucleotides following IUPAC codes.
bLocations given with respect to the ATG start codon.
cTm, annealing temperature in PCR.
Table 2. Regulatory element of the GR promoter region can be pre-
dicted by in silico phylogenetic footprinting
Promoter Transcription
factor
Identiﬁcation
technique
ISPF Prediction
1B SP1 (x3) RG, FP, E 5,4,5 3
1B–D YY-1 (x3)
a FP, D, E 5
b,4,4 3
1D n/d
1E n/d
1F NGFI-A ChIP 5 3
1G n/d
1H n/d
n/d: Not experimentally determined.
aYY-1-binding site initially identiﬁed as part of promoter 1B, subse-
quent identiﬁcation of alternate ﬁrst exons would suggest that it is
part of promoter 1D.
bThis YY-1-binding site is outside the CpG island and not considered
further.
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18-20 was observed in 4, 15 and 4 donors,
respectively.
Promoters 1Jand 1E
Bisulphite sequences of 269bp covering the complete pro-
moter 1E, exon 1J and part of promoter 1J were obtained
(Figure 1). Of the 28 potential CpG methylation sites,
12 were successfully sequenced: four in promoter 1J,
four in exon 1J, and four in the promoter region immedi-
ately upstream of exon 1E (Figure 3). Each of these sites
(except CpG
27) was methylated in one to three of the
26 donors. Interestingly, the in silico analysis identiﬁed
nine TFBS that are evolutionarily highly conserved and
present in at least four of the ﬁve species. However, only
two of these nine sites contain CpG di-nucleotides: Pax3
(-4067) in promoter 1J (CpG
16), and Sp3 (-4012) in
promoter 1E (CpG
19). Bisulphite sequencing of these
nucleotides showed that whilst methylation was possible
it was nevertheless rare (one and three donors, respectively
at levels below 50%).
The bisulphite sequenced region included exon 1J, and
the ﬁrst 24 nucleotides of exon 1E. Exon 1J contains four
CpG dinucleotides (CpG
20–23, Figure 3), whilst exon 1E
contains only one (CpG
28). Within these ﬁve exonic CpG
dinucleotides, the methylation levels were similar to those
in the neighbouring positions.
The methylation of CpG
27 (six donors, >25% methyla-
tion) was much greater than of the other positions within
promoter 1E, and this position is the closest to the exon
1E TSS. TRANSFAC analysis of this position identiﬁes
an NGFI-A-binding site in the human sequence, but this is
not an evolutionarily conserved position beyond human
and chimpanzee. However, both the rat and mouse
share a CACCCCCTCC sequence, diﬀering by only a
single nucleotide from the known active KROX response
element (ctccccctc) (34). Thus the NGFI-A response
element may be more conserved than predicted by ISPF.
Promoter 1F
ISPF predicted for promoter 1F several high quality
potential TFBS, including the NGFI-A-binding site
reported before (25,35). Since methylation of the corre-
sponding NGFI-A-binding site has been well documented
in the rat, we tried to quantify the level of methylation by
cloning. The FCII PCR products were cloned and 10–12
colonies sequenced. The human NGFI-A core recognition
motif, 50-GCGGGGGCG-30, includes two CpG sites
(CpG
41–42, Figure 4). Both of these positions were
unmethylated in the majority of donors. In only 4 of the
26 donors less than 10% of the colonies screened
were methylated at CpG
41 (50-end of the NGFI-A site).
A similar level of methylation of CpG
42 was found for
only two donors (Figure 4). These results show that
methylation of the NGFI-A site is possible in the
human, but is neither uniform nor frequent. The level of
methylation observed by cloning was in agreement with
the low but detectable levels seen in the sequencing
electropherogram.
The sequence covering CpG
31–33 should be interpreted
with caution as this region corresponds to the primer bind-
ing site of the FCII forward primer. However, this region
covers only one predicted human TFBS, HES1, with an
ISPF value of only 2. Of all the promoters investigated,
1F contains the highest number of conﬁdent ISPF predic-
tions (10 with ISPF>4), and has the highest percentage
(60%) of methylatable CpG dinucleotides. Of the 42 CpG
dinucleotides in promoter 1F, ISPF predictions cover only
CpG
14–15 and CpG
41–42. There was no visible methylation,
however, for any of the 26 donors at either positions
CpG
14 or CpG
15.
DA
DB
DB II
E
E II
FA
FB
FC
FA II
FB II
FC II
HA
HA II
HB
HB II
HC
HC II
HD
HD II
HD III
Gene
Sequenced region
PCR fragments
1-D 1-E 1-B 1-F 1-G¶ 1-C3, 1-C2, 1-C1 1-H
481 165 326 102 194 475
†
2
ATG
340
‡
-4814
-4642
-4598 -3622
-3753
-3774
-3217
§
250 / 22 CpG 269 / 12 CpG 326 / 42 CpG 429 / 54 CpG
Figure 1. Schematic representation of the Glucocorticoid receptor CpG island internal structure, the bisulphite sequencing strategy and primer
locations. Known TFBS are shown as arrows and numbered from the ATG translation start codon in exon 2. § from (32), y from (53),
z homologous to the known rat site (25,27),  the ephemeric exon 1G has only been detected in the rat as its homologue 18.
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Promoter 1H, in contrast to the others, showed consider-
able methylation in up to 20 or 21 of the 26 donors (CpG
41
and CpG
55 respectively, Figure 5). Methylation levels of
individual donors were also much higher than in other
GR promoters, with up to 75% methylation of CpG
41 in
two individuals. ISPF predicts that the region around
CpG
14–18 is evolutionarily the most conserved. Half of
the high-quality ISPF predictions (ISPF>4) contained
CpG dinucleotides. However, methylation of these
positions was limited to CpG
14 and CpG
15 (9 and 16
donors, respectively, all <50%), whilst CpG
16,17 and 18
tcttcctttgccaagatggc
1ggctccagaatcctctggaggc
2ggccccc
3gtagat 
 
4gtctcc
5ggacaagaggcttgctgaaagcctacttctttcctttcacatcagacaatg 
 
cacagggaacc
6gtttacccttgagaaccaaggaaggac
7ggcttaggctaccc
8gc
9g 
 
atc
10gc
11gaacctttgccaagatggtggcc
12gc
13ggggac
14gggctggc
15gacact 
 
gtaccctaccaagatggc
16ggc
17gggc
18ggcttcc
19gggac
20gc
21gcttccccaat 
 
c
22gtcttcaagatgtcagagcagggggagcc
23gcc
24gtcagtctgagc
25gc
26ggc
27 
 
gggaggtgagagagtggctgtgGGCTGTGGCC 
TF  ISPF  
peak 
Location      Core match  Matrix  
match 
Sequence 
YY1  1 -4819  − 1 1.000  0.930  ctttgccaagATGGCggctc 
NF-muE1  2 -4811  − 1 1.000  0.966  agATGGCgg 
YY1  3 -4603  − 16, 17  1.000  0.935  ccctaccaagATGGCggcgg 
NF-muE1  4 -4595  − 16 1.000  0.966  agATGGCgg 
c-Ets-1  (p54)  5 -4584  − 18 – 20  1.000  0.962  ggcggcTTCCGggacg 
Elk-1  6 -4582  − 18 – 20  1.000  0.980  cggcTTCCGggacg 
NRF-2  7 -4581  − 18,  19 1.000  0.965  ggCTTCCggg 
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Figure 2. In silico phylogenetic footprinting and bisulphite sequencing of promoter 1D. (A) In silico phylogenetic footprinting covers the start of the
CpG island 340 nucleotides upstream of exon 1D through to exon 1D. (B) Percentage methylation was measured by direct electropherogram reading
after bisulphite sequencing of 26 donors, covering CpG 6–27. Methylation levels are expressed by colour, levels from the scale at the panel top.
(C) CpG identiﬁers and the unsequenced region of promoter 1D (grey background). (D) All TRANSFAC predicted human TFBS in promoter
1D are signiﬁcant ISPF predictions.
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taggaggctcg gtcccg gcatcg tccaagccttcccg acg cg gcg agctgggg 
 
aagggagctggggcg ggggcttcccg cacg ggcacccctcg ccccacg gccc 
 
tctcctttctcaggacg gaccacg agttcccttccccttggactgagggggaagc 
 
tttgttttatttgtaggggcaggggtcctatgaacg tgatagggtgagcaacg ca 
 
cagagtcg agggcagcaaatgtcaagattcg ggggtggggcctgcaccg ggaa 
 
cttggacg cg ggccctggccg gggtggaagaagaggtcaggagtttcg gaag 
 
gggggctatatttcg ccagcaacttactatttcg cctgcaacttgcttttaagcc 
 
tgccg ccccctgctttccttaatcataataataaaaaaaaagtgcaaagaAATCCA 
 
GCTCG CTGGAGGTTTTGCA 
TF  ISPF 
Peak 
Location  Strand  CpG   Core match  Matrix 
match 
Sequence 
MAZ   -4247  + 8  0.888  0.920  gGGGCGgg 
NGFI-A   -4247  − 8 1.000  0.895 
0.923 
ggggcGGGGGcttc 
NF-κ     -4242  − 9, 10  0.958  gggggcTTCCCgcacg 
E2F   -4237  + 9  0.869  0.838  ctTCCCGc 
HES1   -4189 − 13, 14  1.000  0.941  cggacCACGAgttcc 
Cdc5   − - 0.911  0.817  gcatTTTAAagc 
TATA   − - 1.000  0.950  aTTTTAaagc 
Poly A  3 
5
7
8
9
10
4
6
1
2
 +  -  0.949  0.916 
0.978
tgccTGTATtttgttt 
Pax-3 -4067 − 16 1.000  0.838  cctatgaaCGTGAtagggtga 
GATA-1   -4061 + 16  0.993 aacgTGATAgggtg 
HNF-4   -4049 + 17  0.813  0.809  tgagCAACGcacag 
COUPTF   -4042 − 17, 18  0.927  0.820  cgcacagagtcgaGGGCAgcaaa 
Evi-1  + - 1  0.732  gcaaatgtcAAGATt 
Sp3 -4012 + 19 0.925  0.882  attcggggGTGGGg 
MAZR  + -  0.930  0.949  gggggTGGGGcct 
E2F-1   -3992 − 20 0.873  0.907  ccGGGAAc 
COUPTF   − - 1.000  0.843  gggtggaagaagaGGTCAggagt 
NF-κ     -3948 − 24 0.774  0.796 
0.937
caggagTTTCGgaagg 
Elk-1   -3944 + 24  1.000
0.910
agtttCGGAAgggg 
MEF-2   -3930 + 25  0.962  0.876  ggcTATATttcg 
RFX1  (EF-C)  -3923 − 25 0.765 tttcgccaGCAACt 
Pax   + -  0.818  0.823  CTGCAacttgc 
GATA-1   − - 1  0.967  tcctTAATCataat 
HNF-1   -3913 + 26  0.952  0.835 aacTTACTatttcgcctg 
NGFI-A -3877  + 27  1.000  0.894  gccgCCCCCtgct 
C 
A 
B 
D 
0
Figure 3. In silico phylogenetic footprinting and bisulphite sequencing of promoters 1J and 1E. (A) In silico phylogenetic footprinting covers the
end of exon 1D through promoter 1J, exon 1J, to exon 1E. (B) Percentage methylation was measured by direct electropherogram reading
after bisulphite sequencing of 26 donors, covering CpG 16–27. Methylation levels are expressed by colour, levels from the scale at the panel top.
(C) CpG identiﬁers and the unsequenced region of promoter 1J (grey background). Exon 1J is underlined. (D) TRANSFAC prediction for promoter
1J and E. Signiﬁcant ISPF predictions are numbered corresponding to (A). Predictions in bold are high-quality ISPF predictions containing
CpG dinucleotides.
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gtacg tatgcg ccg acccccgctatcccg tcccttccctgaagcctccccagagg 
 
gcg tgtcaggccg cccg gccccg agcg cg gccg agacg ctgcg gcaccg
 
tttccg tgcaaccccg tagcccctttcg aagtgacacacttcacg caactcg g 
 
cccg gcg gcg gcg gcg cg ggccactcacg cagctcagccg cg ggaggc 
 
g ccccg gctcttgtggcccg cccg ctgtcacccg caggggcactggcg gcg
 
cttgccg ccaaggggcagagcg agctcccg agtgggtctggagccg cg gagct 
 
gggcg ggggcg ggaaggAGGTAGCG AGAAAAGAAACTG
 
TF  ISPF  Location Strand CpG    Core  match  Matrix 
match 
Sequence 
Evi-1   -3513  − 4 0.757 0.716  tATCCCgtcccttcc 
EBF  + -  0.976 0.928  cTCCCCagagg 
v-Myb -3436  − 14 1.000 0.914 caCCGTTtcc 
MIF-1   -3435  − 14, 15 1.000 0.940  accgtttccgtGCAACcc 
Elk-1 -3434  − 14, 15 1.000 0.936  ccgtTTCCGtgcaa 
RFX1 -3434 + 14,  15 1.000 0.924  ccgtttccgtGCAACcc 
Bach2   − - 0.922 0.915  agtgACACAct 
Pax-3   -3399 + 18,  19  1.000 0.797 gacacactTCACGcaactcgg
AhR:Arnt   -3393 − 18, 19  1.000 0.955  cttCACGCaactcggc 
CCAAT box    -3363 + 25  0.944 0.925  gcgggCCACTca 
HES1   -3326 + 31  0.989 0.970 ggctcTTGTGgcccg 
COUPTF   -3281 − 36, 37  0.927 0.816  gcttgccgccaagGGGCAgagcg
E2F   -3278 + 36  1.000 0.903 tgcCGCCAagg 
HNF-4  DR1    -3276 − 36 0.893 0.799  ccgcCAAGGggca 
NGFI-A  6
7
8
9
10
1
2
3
4
5
− 41, 42 1.000 0.968  tgggcGGGGGcggg 
MAZ -3222 + 42 0.888 0.920 gGGGCGgg 
E2F-1 -3220 − 42 0.935 0.890 gGCGGGaagg 
IRF − - 0.972 0.970  agaaaAGAAActgga 
ICSBP + - 1.000 0.960  gaaaaGAAACtg 
A 
B  C 
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Figure 4. In silico phylogenetic footprinting and bisulphite sequencing of promoter 1F. (A) In silico phylogenetic footprinting covers the end of exon
1B through to exon 1F. (B) Percentage methylation was measured by direct electropherogram reading (CpG
1–30), or sequencing of 10–12 clones per
donor (CpG
31–43) after bisulphite sequencing of 26 donors, covering CpG 1–42. Methylation levels are expressed by colour, levels from the scale
at the panel top. Blank squares indicate positions for which no data was obtainable. (C) CpG identiﬁers within the sequence of promoter 1F.
(D) TRANSFAC prediction for promoter 1F. Signiﬁcant ISPF predictions are numbered corresponding to (A). Predictions in bold are high-quality
ISPF predictions containing CpG dinucleotides.
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gtaagaagcg aggcg ggagggggccg gggcg cg ctcg ctcccccg aggtgccg ct 
 
gggaccg gagacaactcg ggggccg ccg cg ggagcctacaaacttttattagcc 
 
tcg gggagtgggggtggggggctggcaagggccg ggcg acg gtgacg aaaggg 
 
cagcg cg cg ggtgacagcg ctggcctcttcctctccctccg caggcg tcccc 
 
tggccg ggccg agggggaggaacctgacctcg gacg gcg agcg gagccctgt 
 
cg aactgccg ggggcttcg agcctctcattcctcg cg ggaatcctggcctctt 
 
ttctccccctagtgtcccctttccctccaagggggtcg cccg acacccg ttttcg
 
tggtgaacg ctaagccg cg tctgaattttactcg cccg aatatttgcacg cc 
 
accccg gcg cg cccg agcg cg agcccg ggctccg gggaggccccg gcG
 
GCG CCTGGCTTGAGGAGGGCG
57TGCG
58G 
TF  ISPF  Location  Strand  CpG   Core match  Matrix 
match 
Sequence 
MAZ   -2354  + 2  1.000  0.952 cGGGAGgg 
MAZ   -2332  − 6 1.000  0.943  cgCTCCCc 
AP-2Aα  -2264  +  14  0.989  0.947  ttAGCCTcggggagt 
Sp3 -2262 +  14  0.765 0.870  agcctcggGGAGTg 
MAZ  +    1.000  0.936  gGGGAGtg 
NGFI-A 3
4
5
7
6
6
2
1
  −  1.000  0.898  ggagtGGGGGtggg 
CP2   −  0.97  0.885  CTGGCaagggc 
COUPTF   -2221  − 17 – 20  0.927  0.884  gacggtgacgaaaGGGCAgcgcg 
CREB -2220 +  17,  18  1.000 0.946  acggTGACGaaa 
ATF4 -2218 +  18  1.000 0.903  ggTGACGaaagg 
E4F1 -2217  − 18 1.000  0.930  gTGACGaaag 
CREBATF -2217 +  18  1.000 0.954  gTGACGaaa 
HNF4 -2216 +  18  0.860 0.872  tgacGAAAGggcag 
MAZ   − - 1.000  0.921  ctCTCCCt 
Sp3 -2171  − 23, 24  1.000  0.883  cCCTCCgcaggcgt 
COUPTF    -2134  +  27 – 29  1.000  0.814  gaaccTGACCtcggacggcgagc 
Ik-1   -2069  + 34,  35  1.000  0.949 tcgcGGGAAtcct 
E2F-1   -2068  − 34, 35  0.935  0.879  cGCGGGaatc 
E2F   -2067  − 35 0.869  0.828  gCGGGAat 
NF-κ    -2019  − 36, 37  0.752  0.817  agggggTCGCCcgaca 
v-Myb   -2004  − 38 1.000  0.937  acCCGTTttc 
E2F   -1998  + 39  0.790  0.830 ttTCGTGg 
GATA-4   -1962  − 43, 44  0.814  0.792  tcgcccgAATAT 
MINI-20   -1951  +  45  –  48 0.992  0.903  tttgcaCGCCAccccggcgcg 
NF-κ    -1913  + 53  0.812  0.828 gctccGGGGAggcccc 
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Figure 5. In silico phylogenetic footprinting and bisulphite sequencing of promoter 1H. (A) In silico phylogenetic footprinting covers promoter
1H and part of exon 1H. (B) Percentage methylation was measured by direct electropherogram reading after bisulphite sequencing of 26 donors,
covering CpG 1–42. Methylation levels are expressed by colour, levels from the scale at the panel top. Blank squares indicate positions for which no
data was obtainable. (C) CpG identiﬁers within the sequence of promoter 1H and the unsequenced region (grey background). (D) TRANSFAC
prediction for promoter 1H. Signiﬁcant ISPF predictions are numbered corresponding to (A). Predictions in bold are high-quality ISPF predictions
containing CpG dinucleotides.
Nucleic Acids Research, 2008, Vol. 36, No. 22 7215were methylated in 2, 0 and 3 donors, respectively
(all <25%).
DISCUSSION
The results of this study show that the human GR pro-
moter region is extensively methylated, and that levels and
positions of methylation are highly diverse in normal
donors. Although all of the alternative GR promoters
investigated here are in a CpG island, most of the con-
served TFBS contained methylatable CpG sites, suggest-
ing that epigenetic mechanisms operate throughout
the CpG island of this gene. This is the ﬁrst report of
such a comprehensive investigation of a complex CpG
island containing multiple alternative ﬁrst exons each
with its own promoter and TSS.
Sequence patterns predicted unrealistically large num-
bers of TFBS throughout the human GR CpG island. By
identifying evolutionarily conserved regions through inter-
species sequence comparison (‘phylogenetic footprinting’)
(36), and combining it with TRANSFAC TFBS predic-
tions, a technique we term in silico phylogenetic footprint-
ing, the number of putative TFBS was reduced by 3- to
4-fold. The successful prediction of the known TFBS
within the CpG island (27) validated our approach, at
least for the GR. It also suggests that mechanisms of tran-
scription of the alternative 50 mRNA transcript variants
of GR are conserved in mammalian species.
In PBMCs, ﬁve of the seven CpG island promoters are
known to be used (22). In these ﬁve promoters, covering
more than 40% of the 3.2kbp total GR CpG island over
70% of all CpG dinucleotides were methylated.
Methylation of the GR ﬁrst exon promoters occured
throughout the CpG island and aﬀected every promoter.
Within our 26 donors, methylation was variable, but the
majority of positions were methylated at levels above 25%
in at least one donor. Not a single position was methylated
in all donors.
Previously, methylation of only a 100bp section of pro-
moter 1F (37), and 331bp of the constitutively active pro-
moter 1C (38) have been investigated in humans.
In agreement with our results, Lillycrop et al. observed
variable methylation in both the human promoter 1C in
cord blood and its homologue 110 in the rat liver (38,39),
but no methylation levels of individual CpG dinucleotides
were reported. In human hippocampi of both healthy
and depressed individuals methylation of 1F CpG
35–43
was limited to <10% methylation of CpG
35 in 1 of 32
donors, similar to our ﬁndings in PBMCs (37). In the
same study, CpG
43 was almost 100% methylated in all
donors with no methylation in any other site, which is in
contrast to our ﬁndings in PBMCs where CpG
43 was
almost universally unmethylated. Thus, it is not clear to
what extent positions and variability can be extrapolated
from PBMCs to the human brain.
This variability in methylation patterns is in stark con-
trast to the promoter hypo- and hyper-methylation of
large regions, and levels that are either undetectable, or
nearly 100% in tumours. Because of their consistency
CpGislandhypermethylationproﬁles(‘hypermethylomes’)
are now recognised as tumor-speciﬁc markers, similar to
genetic and cytogenetic markers (40–42), for instance in
prostate cancer (43), andin clear cell renal carcinomas (44).
The variability in methylation between donors and
positions may reﬂect an important epigenetic mechanism
suggested by studies both in animals and humans. Weaver
was able to manipulate the methylation patterns by peri-
natal interventions. In the rat brain, methylation of the
Ngﬁ-A-binding site in promoter 17 was virtually complete
in animals that had received poor postnatal maternal care,
whilst those receiving better maternal care were virtually
unmethylated (25,26,45). By cross fostering pups between
dams providing good or poor post-natal care the pups
developed the epigenome of the foster mother. Similarly,
methylation of promoter 110 was reduced in pups born to
dams fed on a protein-restricted diet during pregnancy
(38,39). These rat experiments suggest that Gr expression
and perhaps sensitivity can be ﬁne-tuned as the host
adapts to its environment during early life. Recent
human data from the GR support the above rat data
(46). Although in the latter study methylation levels
observed were very low, methylation of exon 1F in fetal
cord blood was sensitive to maternal mood. Thus the het-
erogeneity of methylation patterns observed in all the
CpG island dinucleotides and in particular the diﬀerent
alternative GR promoters reﬂect a mechanism of epige-
netic programming of GR ﬁne tuning programmed
by diﬀerences in early life environment and events.
Methylation of these important evolutionarily conserved
TFBS containing methylatable CpG dinucleotides would
suggest that such methylation will have considerable
eﬀects on the transcription from the TSS immediately
downstream. In both these cases, the methylation of
single CpG dinucleotides within the promoter that has
been implicated. Therefore, the observed variability both
in levels and positions of methylation may reﬂect some
speciﬁcity. Methylation of diﬀerent TFBS within a pro-
moter will modulate the promoter response, in a tightly
controlled individualised fashion. Data from other genes
support the role of the inter-uterine environment in lasting
epigenetic conditioning. In a rodent type 2 diabetes model,
Park et al. (47) showed that retarded interuterine growth
resulted in lower Pdx1 levels, a key correlate of adult b cell
function. As for the GR, the Pdx1 promoter is in a CpG
island. Methylation of the 14 CpG pairs in the 275bp
promoter region was shown to be responsible for the
reduced Pdx1 levels. Since methylation modulates pro-
moter activity the highly individual methylation patterns
of GR promoters strongly suggest highly individualised
ﬁne tuning of GR expression. However, many other fac-
tors such as age (7) and drug intake (48–50) may inﬂuence
and add to this variability.
CpG methylation has also been implicated in tissue-
speciﬁc regulation. GNAL (51) and PNP22 (52) are such
examples, but both genes have a simpler structure with
alternative ﬁrst exons and promoters in independent
CpG islands. The tissue-speciﬁc expression of Toll-like
receptor 2 (TLR2) is, however, the result of strong methyl-
ation of the 20 CpG pairs in the  220bp proximal
promoter in the upstream CpG island. This promoter is
very similar in size and number of CpG pairs as each of
7216 Nucleic Acids Research, 2008, Vol. 36, No. 22the individual GR promoters investigated here. Although
ubiquitously expressed, in most tissues functional levels of
GR are tightly and individually regulated in all tissues. We
have previously observed that the multiple alternative
GR ﬁrst exons are expressed in a tissue-speciﬁc manner
each using its own promoter (22,27). Since the complete
GR CpG island with all the promoters can be methylated
we further propose that CpG methylation orchestrates
alternative ﬁrst exon usage and silencing.
Currently an incredible transcriptional variability, espe-
cially in the 50 region unfolds. Already in 2006 the number
of genes with multiple alternative ﬁrst exons has passed
7600 (21), and at least 43 genes have more than 10 ﬁrst
exons. Many of these genes are expressed in a tissue-
speciﬁc manner. With 78% of the evolutionarily conserved
alternative ﬁrst exons falling into CpG islands epigenetic
modulation and tissue-speciﬁc expression through methyl-
ation of individual promoters within CpG islands is bound
to be a biologically important and widely used mechanism
throughout many phyla.
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